RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Intra-Cellular Therapies - Stock

Intra-Cellular Therapies Employees 2024

Intra-Cellular Therapies Employees

383

Ticker

ITCI

ISIN

US46116X1019

WKN

A1XDTL

In 2024, Intra-Cellular Therapies employed 383 people, a 0% change from the 383 number of employees in the previous year.

Intra-Cellular Therapies Aktienanalyse

What does Intra-Cellular Therapies do?

Intra-Cellular Therapies Inc is a biopharmaceutical company that focuses on developing innovative therapies for mental disorders and other severe diseases. The company was founded in 2002 in New York City and is now headquartered in Montvale, New Jersey. Intra-Cellular Therapies' business model is based on identifying and researching novel compounds that target the restoration of balance of certain neurotransmitters in the brain. The company has a wide range of technologies and development programs to validate and optimize its therapy approaches. Intra-Cellular Therapies operates in two main business areas: neurology and oncology. However, the company's focus is on developing compounds for mental disorders such as schizophrenia, bipolar disorder, or depression. One of the company's main compounds is Lumateperone, a new medication for the treatment of schizophrenia. Lumateperone has shown promising results in clinical studies and has the potential to provide significant improvement for patients with schizophrenia, particularly in terms of cognitive function and the negative symptom profile. Intra-Cellular Therapies is currently working on the approval of Lumateperone by the US Food and Drug Administration (FDA). Another important compound is ITI-007, a non-sedative atypical antipsychotic that aims to restore the balance of dopamine and serotonin in the brain. The substance has shown superior efficacy over standard medications in clinical studies and could be a new treatment option for patients with bipolar disorder and schizophrenia. Intra-Cellular Therapies plans to launch ITI-007 in the coming years. In addition to neurology, Intra-Cellular Therapies is also developing compounds for oncology. The company's main compound in this area is ITI-333, a novel inhibitor of the protein Factor VIIa, which could be used as a potential cancer therapy. ITI-333 is currently in preclinical development. In the past years, Intra-Cellular Therapies has made significant progress in developing new compounds and now has a promising product pipeline. The company has also formed partnerships with other pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals to further strengthen its technologies and development programs. Overall, Intra-Cellular Therapies Inc has established itself as one of the leading innovators in the field of neuropsychiatry and could play a significant role in the development of new therapeutics for mental disorders and other severe diseases in the coming years. Intra-Cellular Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Intra-Cellular Therapies's Employee Base

Intra-Cellular Therapies's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Intra-Cellular Therapies's operational capacity and future potential.

Year-to-Year Comparison

Assessing Intra-Cellular Therapies's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Intra-Cellular Therapies's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Intra-Cellular Therapies’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Intra-Cellular Therapies Stock

How many employees does Intra-Cellular Therapies have this year?

Intra-Cellular Therapies has 383 undefined employees this year.

How many employees did Intra-Cellular Therapies have compared to the previous year?

Compared to the previous year, Intra-Cellular Therapies had 0% more employees.

What impact did the number of employees have on the company Intra-Cellular Therapies?

The number of employees has a direct impact on the efficiency and productivity of Intra-Cellular Therapies. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Intra-Cellular Therapies?

The number of employees can also have an impact on investors of Intra-Cellular Therapies, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Intra-Cellular Therapies affect the company?

An increase in equity of Intra-Cellular Therapies can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Intra-Cellular Therapies's equity affect the company?

A reduction in equity of Intra-Cellular Therapies can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Intra-Cellular Therapies?

Some factors that can influence the equity of Intra-Cellular Therapies include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Intra-Cellular Therapies so important for investors?

The equity of Intra-Cellular Therapies is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Intra-Cellular Therapies influence the company?

The number of employees at Intra-Cellular Therapies can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Intra-Cellular Therapies evolved in recent years?

In recent years, the number of employees at Intra-Cellular Therapies has changed by 0.

How many employees does Intra-Cellular Therapies currently have?

Intra-Cellular Therapies currently has 383 undefined employees.

Why is the number of employees important for investors of Intra-Cellular Therapies?

The number of employees is important for investors of Intra-Cellular Therapies as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Intra-Cellular Therapies take to change the number of employees?

To change the number of employees, Intra-Cellular Therapies can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Intra-Cellular Therapies pay?

Over the past 12 months, Intra-Cellular Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intra-Cellular Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Intra-Cellular Therapies?

The current dividend yield of Intra-Cellular Therapies is .

When does Intra-Cellular Therapies pay dividends?

Intra-Cellular Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intra-Cellular Therapies?

Intra-Cellular Therapies paid dividends every year for the past 0 years.

What is the dividend of Intra-Cellular Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intra-Cellular Therapies located?

Intra-Cellular Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intra-Cellular Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intra-Cellular Therapies from 6/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Intra-Cellular Therapies pay the last dividend?

The last dividend was paid out on 6/17/2024.

What was the dividend of Intra-Cellular Therapies in the year 2023?

In the year 2023, Intra-Cellular Therapies distributed 0 USD as dividends.

In which currency does Intra-Cellular Therapies pay out the dividend?

The dividends of Intra-Cellular Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Intra-Cellular Therapies stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Intra-Cellular Therapies

Our stock analysis for Intra-Cellular Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intra-Cellular Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.